Notícias Acurx Pharmaceuticals Inc - ACXP | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Acurx Pharmaceuticals Inc (ACXP)
Acurx Pharmaceuticals Inc (ACXP) Notícias

Acurx Pharmaceuticals Inc (ACXP)

0,8082

0,0572

(7,62%)

Fechado 10 Janeiro 6:00PM

Atrasado por 15 minutos

0,838

0,0298

( 3,69% )

Pré-mercado: 6:02AM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium

New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PT

ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference

New to The Street Announces Episode 590, Five Corporate Interviews, Airing on the Fox Business Network, Tonight Monday, August 19, 2024, at 10:30 PM PT

New to The Street TV Announces Episode 583, Five Riveting Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024, at 6:30 PM ET

Form 8-K - Current report

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update

USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome

Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

1
2
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Acurx Pharmaceuticals

Mitsu Hc Cap.28

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições